2014
p53 protein aggregation promotes platinum resistance in ovarian cancer
Yang-Hartwich Y, Soteras MG, Lin ZP, Holmberg J, Sumi N, Craveiro V, Liang M, Romanoff E, Bingham J, Garofalo F, Alvero A, Mor G. p53 protein aggregation promotes platinum resistance in ovarian cancer. Oncogene 2014, 34: 3605-3616. PMID: 25263447, DOI: 10.1038/onc.2014.296.Peer-Reviewed Original ResearchConceptsPro-apoptotic functionP53 aggregationProtein aggregationP53 aggregatesNormal transcriptional activationTwo-dimensional gel electrophoresisCancer cellsCancer cell survivalKey transcriptional factorGenetic mutationsHigh-grade serous ovarian carcinomaP53 inactivationP53 proteinStem cell propertiesCancer stem cell propertiesCellular homeostasisTranscriptional activationCancer stem cellsTranscriptional factorsTumor-initiating capacityP53 turnoverCell survivalHGSOC cellsStem cellsPotential therapeutic targetDetection of p53 Protein Aggregation in Cancer Cell Lines and Tumor Samples
Yang-Hartwich Y, Bingham J, Garofalo F, Alvero AB, Mor G. Detection of p53 Protein Aggregation in Cancer Cell Lines and Tumor Samples. Methods In Molecular Biology 2014, 1219: 75-86. PMID: 25308263, DOI: 10.1007/978-1-4939-1661-0_7.Peer-Reviewed Original ResearchConceptsCancer cell linesPro-apoptotic functionAggregation of p53P53 proteinCancer cellsCell linesP53 aggregationAmyloid-like oligomersProtein aggregationApoptotic signalsInactive conformationTumor samplesFunctional p53ProteinGenetic mutationsTumor progressionCentral roleP53Dysfunctional p53 proteinCellsAggregationMutationsApoptosisDeregulationLines
2011
Minimal Uterine Serous Carcinoma With Extrauterine Spread
Flynn C, Hui P. Minimal Uterine Serous Carcinoma With Extrauterine Spread. Advances In Anatomic Pathology 2011, 16: 104-107. DOI: 10.1097/pcr.0b013e31821734fe.Peer-Reviewed Original ResearchMinimal uterine serous carcinomaUterine serous carcinomaSerous carcinomaEndometrial polypsSerous endometrial intraepithelial carcinomaEndometrial intraepithelial carcinomaExtrauterine diseaseConventional serous carcinomasExtrauterine spreadAbdominal carcinomatosisIntraepithelial carcinomaMüllerian carcinomasImmunohistochemical profileMutant p53 proteinPatient's diseaseCarcinomaDiseaseP53 proteinPolypsPresumed originCarcinomatosisPostmenopausalPatientsUterusTumors
2009
p53 responsive elements in human retrotransposons
Harris CR, DeWan A, Zupnick A, Normart R, Gabriel A, Prives C, Levine AJ, Hoh J. p53 responsive elements in human retrotransposons. Oncogene 2009, 28: 3857-3865. PMID: 19718052, PMCID: PMC3193277, DOI: 10.1038/onc.2009.246.Peer-Reviewed Original ResearchConceptsP53-responsive elementResponsive elementHuman genomeL1 promoterL1 elementsP53 DNA binding sitesRepetitive DNA elementsDNA binding sitesL1 mRNAP53 proteinCytosine methylationNuclear element-1DNA elementsGenomic stabilityHuman retrotransposonsP53-dependent processesGenomic changesGenomic protectionGenomeElement 1L1 mRNA expressionProteinBinding sitesPromoterL1 protein
2006
p16INK4a Modulates p53 in Primary Human Mammary Epithelial Cells
Zhang J, Pickering CR, Holst CR, Gauthier ML, Tlsty TD. p16INK4a Modulates p53 in Primary Human Mammary Epithelial Cells. Cancer Research 2006, 66: 10325-10331. PMID: 17079452, DOI: 10.1158/0008-5472.can-06-1594.Peer-Reviewed Original ResearchConceptsPrimary human mammary epithelial cellsHuman mammary epithelial cellsMammary epithelial cellsCell type-specific regulationTumor suppressor geneStabilization of p53Epithelial cellsP53 protein levelsE2F/Gene activityDownstream targetsCellular responsesSuppressor geneProteolytic degradationProtein levelsP53 proteinP16 proteinP53ProteinReduced levelsP53 statusPathwayCellsGenesRegulation
2005
Minimal uterine serous carcinoma: a clinicopathological study of 40 cases
Hui P, Kelly M, O'Malley DM, Tavassoli F, Schwartz PE. Minimal uterine serous carcinoma: a clinicopathological study of 40 cases. Modern Pathology 2005, 18: 75-82. PMID: 15389257, DOI: 10.1038/modpathol.3800271.Peer-Reviewed Original ResearchConceptsMinimal uterine serous carcinomaUterine serous carcinomaSerous carcinomaEndometrial polypsExtrauterine tumorsInvasive serous carcinomasSurgical staging procedureHigh nuclear gradeSurgical stagingClinicopathological studyOverall survivalStaging procedureClinical outcomesClinicopathologic featuresStromal invasionImmunohistochemical profileNuclear gradeMutant p53 proteinCarcinomaPatientsPolypsTumorsP53 proteinLesionsInvasion
2003
Chromosome stability, in the absence of apoptosis, is critical for suppression of tumorigenesis in Trp53 mutant mice
Liu G, Parant J, Lang G, Chau P, Chavez-Reyes A, El-Naggar A, Multani A, Chang S, Lozano G. Chromosome stability, in the absence of apoptosis, is critical for suppression of tumorigenesis in Trp53 mutant mice. Nature Genetics 2003, 36: 63-68. PMID: 14702042, DOI: 10.1038/ng1282.Peer-Reviewed Original ResearchConceptsTrp53-null miceCell cycle arrestEarly onsetCycle arrestPartial cell cycle arrestMonths of ageTrp53 mutant miceSpontaneous tumorsSpontaneous tumorigenesisRare mutant formMutant miceThymic lymphomasMiceHuman tumorsSuppression of tumorigenesisTumorsAbsence of apoptosisP53 proteinP53-dependent apoptosisInduces ApoptosisLymphomaApoptosisTumorigenesisTumor suppressorP53-induced apoptosis
2000
Mutant p53 protein overexpression in women with ipsilateral breast tumor recurrence following lumpectomy and radiation therapy
Turner B, Gumbs A, Carbone C, Carter D, Glazer P, Haffty B. Mutant p53 protein overexpression in women with ipsilateral breast tumor recurrence following lumpectomy and radiation therapy. Cancer 2000, 88: 1091-1098. PMID: 10699900, DOI: 10.1002/(sici)1097-0142(20000301)88:5<1091::aid-cncr21>3.0.co;2-y.Peer-Reviewed Original ResearchConceptsIpsilateral breast tumor recurrenceMutant p53 protein overexpressionBreast carcinoma patientsP53 protein overexpressionBreast tumor recurrenceDistant disease-free survivalDisease-free survivalCase-control studyPrimary breast tumorsCarcinoma patientsMutant p53 proteinBreast tumor relapseRadiation therapyTumor recurrenceBreast tumorsFree survivalProtein overexpressionPrognostic significanceP53 proteinEstrogen receptorTumor relapseIndex caseP53 mutationsControl casesP53 protein immunoreactivity
1999
Accumulation of p53 protein is frequent in ovarian cancers associated with BRCA1 and BRCA2 germline mutations.
Zweemer R, Shaw P, Verheijen R, Ryan A, Berchuck A, Ponder B, Risch H, McLaughlin J, Narod S, Menko F, Kenemans P, Jacobs I. Accumulation of p53 protein is frequent in ovarian cancers associated with BRCA1 and BRCA2 germline mutations. Journal Of Clinical Pathology 1999, 52: 372. PMID: 10560359, PMCID: PMC1023075, DOI: 10.1136/jcp.52.5.372.Peer-Reviewed Original ResearchConceptsOvarian cancer casesBRCA2 germline mutationsHereditary ovarian cancerOvarian cancerCancer casesP53 accumulationGermline mutationsSomatic genetic eventsInvasive ovarian cancer casesBRCA2 germline mutation carriersOvarian cancer patientsP53 proteinGermline mutation carriersGenetic eventsRole of p53Cancer patientsAntigen retrieval techniqueBRCA mutationsBRCA2 mutationsStudy groupMutation carriersP53 alterationsP53 immunohistochemistryGermline BRCA1Positive casesImmunofluorometric assay of p53 protein versus sequencing of p53 exons 5 to 9 for the detection of p53 abnormalities in ovarian carcinoma.
Lianidou E, Levesque M, Katsaros D, Angelopoulou K, Yu H, Genta F, Arisio R, Massobrio M, Bharaj B, Diamandis E. Immunofluorometric assay of p53 protein versus sequencing of p53 exons 5 to 9 for the detection of p53 abnormalities in ovarian carcinoma. Anticancer Research 1999, 19: 749-56. PMID: 10216487.Peer-Reviewed Original ResearchConceptsP53 protein accumulationOvarian carcinomaP53 abnormalitiesP53 mutationsP53 proteinMissense point mutationsPrimary epithelial ovarian carcinomaEpithelial ovarian carcinomaGrade 3 lesionsCM-1 antibodyP53 protein overexpressionP53 exons 5Exon 5Unfavorable prognosisMutant p53 proteinP53 alterationsSerous histotypeClinical valueStage IIIDO-1Most malignanciesImmunofluorometric assayCarcinomaTumor tissueProtein accumulation
1998
Immunofluorometrically determined p53 accumulation as a prognostic indicator in italian breast cancer patients
Levesque M, Katsaros D, Yu H, Giai M, Genta F, Roagna R, Ponzone R, Massobrio M, Sismondi P, Diamandis E. Immunofluorometrically determined p53 accumulation as a prognostic indicator in italian breast cancer patients. International Journal Of Cancer 1998, 79: 147-152. PMID: 9583729, DOI: 10.1002/(sici)1097-0215(19980417)79:2<147::aid-ijc9>3.0.co;2-t.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAnalysis of VarianceAntibody SpecificityBreast NeoplasmsCarcinoma, Ductal, BreastCombined Modality TherapyDisease-Free SurvivalFemaleFluorescent Antibody TechniqueHumansLymphatic MetastasisMiddle AgedMultivariate AnalysisNeoplasm StagingPredictive Value of TestsPrognosisReceptors, EstrogenReceptors, ProgesteroneRecurrenceSensitivity and SpecificityTime FactorsTumor Suppressor Protein p53ConceptsP53 proteinItalian breast cancer patientsProgesterone receptor expression statusMultivariate Cox regression analysisP53-negative patientsP53-positive patientsReceptor expression statusDisease-free survivalLymph node statusSteroid hormone receptor analysisCox regression analysisBreast cancer patientsEstrogen receptor expressionHormone receptor analysisCM-1 antibodySensitive immunofluorometric assayBreast cancer prognosisP53 protein accumulationOverall survivalPatient ageIndependent predictorsHistologic typeNode statusPrognostic valueShort patientsImmunohistologic Evaluation of Putatively Mutant p53 Protein in Cutaneous Melanocytic Neoplasms
Kaleem Z, Lind A, Humphrey P, Swanson P, Sueper R, Ritter J, Wick M. Immunohistologic Evaluation of Putatively Mutant p53 Protein in Cutaneous Melanocytic Neoplasms. International Journal Of Surgical Pathology 1998, 6: 73-79. DOI: 10.1177/106689699800600203.Peer-Reviewed Original ResearchImmunohistologic evaluationMutant p53 proteinNuclear labelingMelanocytic neoplasmsLentigo maligna melanomaP53 proteinHigh-power microscopic fieldCutaneous melanocytic neoplasmsBenign melanocytic neoplasmsP53 tumor suppressor geneMaligna melanomaNodular melanomaMalignant melanomaLatter lesionsMelanocytic proliferationMelanomaHuman malignanciesMelanocytic lesionsTumor suppressor geneSpitz neviCommon neviGenetic alterationsNeviMp53Neoplasms
1995
Immunofluorometric analysis of p53 protein and prostate-specific antigen in breast tumours and their association with other prognostic indicators
Levesque M, Clark G, Yu H, Diamandis E. Immunofluorometric analysis of p53 protein and prostate-specific antigen in breast tumours and their association with other prognostic indicators. British Journal Of Cancer 1995, 72: 720-727. PMID: 7545416, PMCID: PMC2033897, DOI: 10.1038/bjc.1995.400.Peer-Reviewed Original ResearchConceptsS-phase fractionEpidermal growth factor receptorHER-2/neuProgesterone receptorPrognostic indicatorBreast cancerBreast tumorsProstate-specific antigen expressionIndependent prognostic indicatorP53 proteinProstate-specific antigenAggressive tumor phenotypeWilcoxon rank sum analysisBreast tumor extractsStatus of p53Growth factor receptorPresence of PSARank-sum analysisFavorable prognosisPrognostic factorsBetter prognosisLevels of ERPresence of p53Antigen expressionTumor extractsMutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma
Levesque M, Katsaros D, Yu H, Zola P, Sismondi P, Giardina G, Diamandis E. Mutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma. Cancer 1995, 75: 1327-1338. PMID: 7882283, DOI: 10.1002/1097-0142(19950315)75:6<1327::aid-cncr2820750615>3.0.co;2-p.Peer-Reviewed Original ResearchConceptsEpithelial ovarian carcinomaOvarian carcinomaMutant p53 proteinResidual tumorHistologic gradeOvarian cancerP53 proteinCancer relapseMutant p53 protein overexpressionLonger disease-free survivalKaplan-Meier survival curvesPostsurgical residual tumorDisease-free survivalEarly-stage diseaseSubset of patientsLow histologic gradeMutant p53 protein accumulationAdvanced-stage cancerDifferent clinical stagesP53-negative tumorsP53-positive tumorsP53 protein overexpressionPoor patient outcomesAnti-p53 antibodiesP53 protein accumulation
1994
Overexpression of p53 Is Not a Feature of Benign and Early-Stage Borderline Epithelial Ovarian Tumors
Berchuck A, Kohler M, Hopkins M, Humphrey P, Robboy S, Rodriguez G, Soper J, Clarke-Pearson D, Bast R. Overexpression of p53 Is Not a Feature of Benign and Early-Stage Borderline Epithelial Ovarian Tumors. Gynecologic Oncology 1994, 52: 232-236. PMID: 7508877, DOI: 10.1006/gyno.1994.1037.Peer-Reviewed Original ResearchConceptsEpithelial ovarian tumorsOverexpression of p53Borderline epithelial ovarian tumorsEpithelial ovarian cancerOvarian tumorsBorderline tumorsOvarian cancerEarly-stage borderline ovarian tumorsStage I/II casesBenign epithelial ovarian tumorsInvasive epithelial ovarian cancerBorderline ovarian tumorsBenign ovarian tumorsStage III casesAdvanced stage casesBenign tumorsMutant p53 proteinP53 tumor suppressor gene productIII casesStage casesTumorsII casesP53 proteinTumor suppressor gene productP53Quantitative analysis of mutant p53 protein in breast tumor cytosols and study of its association with other biochemical prognostic indicators in breast cancer
Levesque M, Diamandis E, Yu H, Sutherland D. Quantitative analysis of mutant p53 protein in breast tumor cytosols and study of its association with other biochemical prognostic indicators in breast cancer. Breast Cancer Research And Treatment 1994, 30: 179-195. PMID: 7524772, DOI: 10.1007/bf00666062.Peer-Reviewed Original ResearchConceptsCarcinoembryonic antigenPrognostic indicatorBreast cancerBreast tumorsBiochemical prognostic indicatorsCandidate prognostic indicatorBreast tumor cytosolsSteroid hormone receptorsNegative associationProgesterone receptorTumor cytosolsMutant p53 proteinTumor extractsP53 tumor suppressor gene productSpecific antigenBiochemical parametersObserved associationsHormone receptorsImmunofluorometric procedureStrong positive associationCognate steroid ligandP53 proteinReceptorsStrong negative associationTumor suppressor gene product
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply